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Early thymic T cell development in young transgenic mice over-expressing human 
Cu/Zn Superoxide Dismutase, a model of Down’s syndrome. 
 
ABSTRACT  
Previous studies have shown that transgenic mice over-expressing Cu/Zn Superoxide 
dismutase, a model of Down’s syndrome, exhibit premature thymic involution. We have 
performed an extensive multiparametric flow cytometry analysis of the developing thymus in 
these homozygous transgenic mice (hSOD1/hSOD1: Tg-SOD). Longitudinal follow-up 
analysis from day 3 to day 280 showed an early thymic development in Tg-SOD mice as 
compared with controls. This thymic early development was associated with an increased 
migration of mature T cells to peripheral lymphoid organs. BrdU labeling showed no 
difference between Tg-SOD and control mice, confirming that the greater number of 
peripheral T cells in Tg-SOD mice was not due to extensive proliferation of these cells but 
rather to a greater pool of emigrant T cells in Tg-SOD. 
 
Keywords:  Cu/Zn Superoxide dismutase (SOD1), Down’s syndrome, Lymph 
nodes, Reactive oxygen species (ROS), Spleen, Thymus, Transgenic, T 
lymphocytes,  
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INTRODUCTION 
The human Copper/Zinc (Cu/Zn)-dependent SuperOxide Dismutase (hSOD1) enzyme 
catalyses the dismutation of O2 to H2O2 and O2
. 
. The hSOD1 gene is located on chromosome 
21 in q22.1 and the SOD1 enzymatic activity is consequently over-expressed in trisomy 21, or 
Down's syndrome (DS) persons [1, 2].  DS is associated with humoral and cellular 
immunological abnormalities [3-6], which are more pronounced in aged patients [7, 8]. 
Moreover altered histology of the lymphoid and epithelial compartments of the thymus has 
been widely demonstrated [9-12]. Most typical changes in DS thymus include elimination of 
lymphocytes from the cortical and medullar areas, formation of giant cystic thymic bodies 
with necrosis, and hyper- or hypoplasia of the reticuloepithelium. In some reports, these 
changes are considered as the primary cause of immunodeficiency associated with 
reticuloepithelial pathology, while in others, they rather are considered as secondary 
manifestations of increased thymic involution which is a complex age-related process [13-17]. 
 It has been proposed that thymic involution is due to alterations in intrathymic T-cell 
development although changes primarily affecting stromal elements of the thymus cannot be 
excluded [18]. To explore the possible role of SOD1 over-expression in the premature thymic 
involution and immune disorders observed in DS patients, transgenic mice over-expressing 
the human SOD1 gene (hSOD1 Tg mice) were generated [19]. Transgenic mice 
overexpressing SOD1 has been shown to have thymic abnormalities [20-22]. More recently 
the Ts65Dn mice, modeling human trisomy 21, has been shown also to have abnormal thymic 
apoptosis properties in which reactive oxygen species are involved [23]. The early stages of 
thymic development represent crucial steps for the production of mature T cells [24, 25]. In 
neonatal and young adult mice, the thymus considerably increases in size and is associated 
with significant proliferation of both thymocytes and the supporting stromal elements. Thus 
Early thymic development in SOD1 transgenic mice. 
 
 4 
thymic dysfunction in hSOD1 Tg mice can be either due to the results of primary immune 
deficiency or early senescence. [26-29]. As early senescence might be the result of premature 
T cell differentiation, we have studied the early steps of T cell differentiation both in thymus 
and peripheral organs of transgenic mice for the human SOD1 gene (Tg-SOD). In this 
context, we performed an extensive analysis in the thymus and peripheral organs of T 
lymphocyte development: double negative (DN) cells, which expressed neither CD4 nor CD8 
antigen, double positive (DP) cells, which expressed both CD4 and CD8, and simple positive 
(SP) cells, which expressed either CD4 or CD8. Thymocytes differentiate from DN to DP and 
then SP cells. At the DP stage, the TCR composed of an alpha/beta heterodimer is expressed 
for the first time in association with CD3 [30-32]. Up-regulation of the CD69 antigen 
expression can be used as an indicator of positively selected (DP) cells on the way to single 
positive cells  [33-35]. 
 Precise analysis by multi-parameter flow cytometry showed that early thymocyte 
differentiation was altered in Tg-SOD mice and was associated with an increased migration of 
mature T cells to peripheral lymphoid organs.  
 
MATERIALS AND METHODS 
Mice  
Thymus, spleen and lymph nodes were obtained from transgenic (Tg) mice over-expressing, 
on the FVB/N strain background, the human superoxide dismutase Cu/Zn (hSOD1) gene 
including its own promoter (KT line, 21). All the Tg mice used in the present study were 
homozygous for the hSOD1 transgene (Tg-SOD). Non-transgenic mice (ntg) FVB/N used as 
controls were obtained in our own animal facilites. Animals aged from 3 to 280 days were 
maintained under specific pathogen-free conditions in the animal facility of the DRDC/CEA-
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Grenoble. The entire research protocol adhered to the guidelines of the European Council 
directive (86/609/EEC). 
 
Superoxide dismutase activity 
For SOD activity, thymus cells were washed three times, resuspended in 10ml of isotonic, 
trace element-free Tris-HCl buffer (400mM, pH 7.3), and lysed in hypotonic Tris-HCl buffer 
(20mM) by 5 cycles of freezing and thawing. After 10 minutes of centrifugation at 4,000 rpm, 
4°C, the lysate was assayed for metalloenzyme activities and soluble protein content. Total 
SOD activity corresponding to the sum of the Manganese (Mn)-dependant SOD (SOD2) and 
the Cu/Zn SOD (SOD1) activities, was determined spectrophoto- metrically (320nm) using 
pyrogallol assay [36]. SOD2 is determined by blocking specifically the SOD1 activity with 
KCN; the difference between total SOD and SOD2 activities allow to determine the SOD1 
activity. The amount of SOD inhibiting the reaction rate by 50% in the given assay conditions 
was defined as one SOD unit. Each sample was analyzed in duplicate, and results were 
expressed as SOD units and normalized to cell protein content. 
 
Flow cytometry analysis 
Cells were stained at 1x10
6
 cells in 50l staining buffer (PBS, 1% FBS, 0.01% NaN3) 
so-called FACSwash, and incubated for 15 min at 4°C in the wells of round-bottom 96-well 
microtiter plates containing saturating concentrations of labeled monoclonal antibodies (mAb) 
in 150l FACSwash. Labeled mAb CD8FITC, CD8cychrome, CD4PE, CD4cychrome, 
CD3Cychrome, TCRαβbiotin, CD69biotin  (PharMingen, San Diego, CA, USA). Following 
washing in FACSwash, biotin-labeled antibodies were revealed with APC-conjugated 
streptavidin (SA
APC.
) (PharMingen). Cell samples were analyzed by three or four color flow 
cytometry using a FACSCalibur instrument (Becton-Dickinson, Becton-Dickinson, Le Pont 
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de Claix, France) and data analyzed using FCSExpress software (Denovo software, Ontario, 
Canada). For each sample at least 3x10
5
 cells, gated on a combination of forward (FSC) and 
side (SSC) scatter, were acquired. 
 
BrdU labeling 
One month-aged mice were given 1 mg BrdU i.p. and subsequently given BrdU in 
their drinking water 1 mg/ml. Cells stained with anti-CD8
cychrome
, anti-CD4
PE
 monoclonal 
antibodies (PharMingen) were fixed, permeabilized and stained with FITC-labeled anti-BrdU 
antibody using the BrdU Flow Kit (PharMingen) according to the manufacturer’s instructions. 
Cell samples were analyzed by three color flow cytometry using a FACSCalibur instrument. 
 
Cytokine production 
Analysis of individual cytokine-producing cells within mixed populations was carried out 
with the intracellular cytokine staining kit from PharMingen according to the manufacturer’s 
instructions. Briefly, spleen cells from 1-month-old mice were suspended in D-MEM at 1x10
6
 
cells in 24-well plates, and stimulated for 4 hours with anti-CD3 monoclonal antibody in the 
presence of the intracellular protein transport inhibitor Brefeldin-A (GolgiStop from 
PharMingen). Harvested cells were then washed and incubated in 50µl of staining buffer in 
96-well plates containing a mixture of anti-CD8
FITC
 and anti-CD4
cychrome
 mAb for 15 min at 
4°C. After staining cells were washed, fixed and permeabilized with 100 µl of 
Cytofix/Cytoperm
TM
 solution. Permeabilized cells were then washed and suspended in 
Perm/Wash
TM
 solution for 15 min and stained for intracellular cytokines using a cocktail of 
PE conjugated anti-cytokine antibodies, IL-2
PE
, IL-10
PE
, IFN-γPE and TNF-αPE. After a final 
wash, cells were analyzed by three color flow cytometry using a FACSCalibur instrument. 
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RESULTS 
Activity of SOD1 in the Tg-SOD mouse thymus. 
Previous studies with hemizygous hSOD1 Tg (hSOD1/+) mice more than 6 months-old from 
the same line  (KT) indicated an early involution of the thymus architecture [20, 21]. 
However, no information was yet available concerning the putative effects of the hSOD1 on 
thymic development in young mice. In preliminary experiments, we measured the activity of 
total SOD1 activity in the thymus of non-transgenic control and transgenic mice as previously 
described [36]. In subsequent studies, we used only homozygous hSOD1 transgenic (Tg-
SOD) and non-transgenic from the same littermate as control (ntg) mice as controls on the 
same inbred background (FVB/N). Enzymatic SOD1 activity assays were performed in Tg-
SOD mice at 1 and 3 months of age (data not shown). At 1 month of age, the SOD1 activity 
was five times greater in homozygous Tg-SOD mice (102  20 U/mg of protein) than in ntg 
controls (22  6 U/mg of protein). At 3 months of age, SOD1 activity was decreased but still 
higher in Tg-SOD (58  10 U/mg of protein) than in ntg (15  11 U/mg of protein) mice. 
 
Early transient hypertrophy of the Tg-SOD mouse thymus 
Thymus cellularity in Tg-SOD mice was determined by counting viable thymus cells in mice 
from 3 to 280 days of age. As shown in table 1, the thymus of Tg-SOD was larger than 
controls (30x10
6
 versus 7x10
6
 at day 3 and 159 x10
6
 versus 58 x10
6
 at day 84). In both Tg-
SOD and ntg, thymus cellularity reached a maximum at day 21 (563x10
6
 in Tg-SOD versus 
245x10
6 
cells in ntg). From day 21, thymus cellularity decreased significantly in both animals, 
reaching relatively stable numbers after 84 days in ntg and after 140 days in Tg-SOD (48x10
6
 
versus 49x10
6
 at 140 days); until this latter time point, the thymus in Tg-SOD mice was 
always larger than in ntg. After 140 days the cellularity was stable and similar in both types of 
mice (39 x10
6
 versus 35 x10
6
 at 280 days). To compare relative thymic development in Tg-
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SOD versus ntg mice, we normalized the maximum thymic cellularity at day 21 to 100% in 
both mice. Thymus growth was accelerated in Tg-SOD reaching 6% (versus 3% in ntg) at day 
3, 49% (versus 25% in ntg) at day 6, 87% (versus 50% ntg) at day 14. In older mice, since 
140 days, involution of the thymus was more rapid in transgenic than control mice, with 
thymus cellularity down at containing only 9% of maximum in transgenic versus 22% in ntg 
controls. In conclusion, thymus of Tg-SOD mice as compared with control mice, displayed a 
hypertrophy due to an accelerated growth in the first three weeks of live, which regressed 
more rapidly with age.  
 
Thymocyte differentiation in Tg-SOD mouse thymus 
In order to determine which steps of the thymus development were affected; thymocytes were 
harvested at days 3, 6, 14, 21, 84 and 140, and were analyzed for the expression of 
differentiation markers by the mean of mAb specific for CD8
FITC
, CD4
PE
, CD3
CY
 and TCRβ 
APC
 or CD69
APC
. At day 3, there was an increase of about 1.8 times in the proportion of both 
CD4
+
 and CD8
+
 SP in Tg-SOD, with 12.6±1.2% and 1.5±0.4% respectively (Fig 1A, upper 
left), as compared to ntg, with 7.2±0.5% and <1% respectively (Fig 1A, down left). At day 21, 
when thymus size is maximum for Tg-SOD and control mice, these values, reached 
21.5±0.8% versus 12.1±0.9% for CD4
+
 cells and 4±0.4% versus 1.7±0.6% for CD8
+
 cells in 
Tg-SOD versus ntg mice, (Fig 1A. upper right). Fig. 1 B and C show the numbers of CD4
+
 
(B) and CD8
+
 (C) SP cells in the thymus of mice at different ages. Until day 100, the numbers 
of both SP cells type were greater in Tg-SOD mice than in ntg. Altogether these data showed 
that the number of differentiated thymocytes were temporary increased in mice over-
expressing human SOD1, even if the ratio CD4/CD8 is almost the same in both types of mice. 
 
 
Early thymic development in SOD1 transgenic mice. 
 
 9 
Expression of TCR and activation marker in early thymocyte maturation  
As total SP thymocytes were dramatically increased in Tg-SOD mice as compared with ntg 
controls, we analysed various steps of thymocyte differentiation. We investigated the DP and 
SP cells for the expressions of TCR and CD69, which successively expressed during the 
process of differentiation and cell activation. For DP T cells, the expression of TCRβ was 
similar in both Tg-SOD and ntg mice (Figure 2A. upper panel). For instance, at day 21, the 
proportion of DP cells expressing high level of TCRβ (indicated by the horizontal bar above 
the histograms) is 18.9±2.6% in Tg-SOD mice (grey area) expressed a high level of TCRβ 
versus 6.5±1.5% in ntg (black area). For SP T cells, at day 3, 88±9.7% of the CD4
+
 and 
84±9.7% of the CD8
+
 SP T cells in Tg mice expressed a TCRβ complex versus 67±7.6% 
(Figure 2A, left panels) and 33±9.7% (data not shown due to the low numbers of events in 
histogram representation) respectively in ntg mice. At day 21, the percent of SP cells 
expressing TCRβ reached 98±0.5% in both Tg-SOD and ntg mice, but the mean of 
fluorescence intensity (MFI) was higher in Tg-SOD mice (Fig 2A. right panels). It is striking 
that TCRβ was expressed at high level in Tg SP lymphocytes. For instance at day 3, in CD4+ 
cells, TCR expression had a MFI of 503±29 for Tg-SOD versus 226±25 for ntg mice (Figure 
2A, left panels), and in CD8
+
 cells the MFI was of 513±18 (Figure 2A, left panels) for Tg 
versus 229±22 for ntg mice (data not shown). Again at day 21, in CD4
+ 
cells TCR 
expression was with a MFI of 837±27 for Tg-SOD versus 610±34 for ntg, and in CD8
+
 cells 
the MFI was 730±45 for Tg-SOD and 582±34 for ntg mice (Fig 2A. right panels). 
A similar phenomenon was observed for CD69 expression (Fig 2B.). The proportions of DP T 
cells expressing of CD69 marker were similarly very low in both Tg-SOD and ntg mice 
(Figure 2B. upper panel). Briefly, at day 3 less than 2% of DP T cells are CD69
+
, then at day 
21 about 7±2.8% of DP express CD69 in Tg-SOD and ntg mice. For SP cells, at day 3, 
42±5.8% of the CD4
+
 and 18±3.4% of the CD8
+
 SP cells in Tg-SOD mice were CD69
+
, 
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versus an average of 2% of both populations in ntg controls. At day 21, CD69 expression had 
increased in SP cells from both Tg-SOD and ntg mice, therefore in Tg-SOD mice the 
proportions of SP CD69
+ 
were greater than in ntg mice. For instance at day 21,  66±16.3% of 
the CD4
+
 T cells from Tg-SOD are CD69
+ 
versus 60±5.1% in ntg mice, and 47±14.5% of 
CD8
+ 
T cells are CD69
+ 
versus 40±4.3% in ntg mice (Fig 2B, right panels). 
Finally, the numbers of CD69
+
 cells in DP, SP CD4
+ 
and SP CD8
+
 T cells follow the same 
overall variation in function of age for both Tg-SOD and ntg mice (Fig2C), reaching a 
maximum number at day 21. The number of CD69
+
 cells was for every experimental point 
greater in Tg-SOD than in ntg mice until day 100.  
In conclusion, the analysis of TCR and CD69 expression revealed some differences in the 
chronology of the differentiation in Tg-SOD versus ntg mice: at day 3 the expression profiles 
of the markers in transgenic SOD mice were similar to those obtained at day 21 in ntg mice.  
 
Increased number of T cells in the periphery of Tg-SOD mice 
As we showed that thymus differentiation was accelerated in the thymus of Tg-SOD mice, we 
examined T lymphocyte populations in the periphery. Phenotypes and cell numbers were 
analyzed for spleen and lymph nodes T lymphocytes. 
In the spleen of 3 day old mice, the cellularity was 3 times greater in Tg-SOD than in ntg 
mice, then after it was almost similar in both types of mice (Table I.). The percentages of 
CD4
+
 and CD8
+
 cells were dramatically higher in Tg-SOD than in ntg mice until 21 days  
of age. At day 3 (Fig 3. upper left), 8.6±1.7% of gated cells were CD4
+
 and 3.5±0.8% CD8
+
 
respectively in Tg-SOD mice. This contrasted with those of 1.2±0.1% and 0.3±0.03% 
obtained in ntg mice (Fig 3. lower left). Moreover, there were 20 times more CD4
+
 (3.9 
versus 0.2x10
6
) and 40 times (1.6 versus 0.004x10
6
) more CD8
+
 cells in transgenic versus 
controls. At day 6, total spleen cellularity was roughly similar (58.9 versus 48.7x10
6
 cells) in 
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Tg-SOD and ntg controls but the population of CD4
+
 and CD8
+
 cells were still higher for 
transgenic with 14±1.5% versus 0.9±0.06% for CD4
+
 and 4±0.7% versus 0.15±0.01% for 
CD8
+
. At day 14, the percentage increased and remained higher in Tg-SOD mice with 
21±1.7% versus 10.1±0.3% for CD4
+
 and 5.4±0.7% versus 3.2±0.4% for CD8
+
. At day 21, 
the percentage of CD4
+
 and CD8
+
 present in spleen of Tg-SOD mice (Fig 3. upper right) 
increased to 45±1.9% (versus 31±0.5%) and 11±0.8% (versus 9±0.8%) (Fig 3, lower right). 
At day 84, there was no difference in the numbers and repartition of T cells in the spleen of 
Tg-SOD and ntg mice (data not shown). 
Lymph node (LN) cell numbers were always greater in Tg-SOD when compared to ntg mice 
(3-fold at day 14 and 2 fold at day 21 and 84) (Table I.). At day 6, lymph nodes from Tg-SOD 
mice contained 11.5x10
6
 cells, of which 63±1.6% were CD4
+
 and 25±1.1% CD8
+
. For ntg 
mice, it was not possible to collect LN at day 6, because of their too tiny size. At day 14, the 
cellularity of the LN was 3 times greater in Tg-SOD mice (37.5 versus 12.3x10
6 
cells) with 
55±4.1% (versus 63±1.5%) CD4
+
 and 23±1.2% (versus 21±0.5%) CD8
+ 
(data not shown). 
Interestingly, the cellularity and T lymphocyte subset distribution in ntg mice at 14 days were 
similar to those observed in 6 day old Tg-SOD mice. At day 21, the cellularity of LN 
increased to 86.7x10
6
 (versus 40.7) in Tg-SOD mice whereas the proportions of T cell subsets 
were similar in both mice, with an average of 45±4.7% for CD4
+
 and 20±2.3% for ntg mice. 
From day 21 to day 84, LN cellularity decreased to reach 34.4x10
6
 (versus 15.7) in Tg-SOD 
mice. 
Altogether, the number of T lymphocytes in the periphery is significantly increased in Tg-
SOD mice. This augmentation occurred as early as day 3 of life. 
 
 
 
Early thymic development in SOD1 transgenic mice. 
 
 12 
Identical proliferation and activation properties of T cells in Tg-SOD mice 
We seek for difference in the distribution of proliferating thymocytes or peripheral T cells 
between one month old Tg-SOD and ntg mice by 4 and 48 hours BrdU labeling experiments. 
After 4 hours of BrdU labeling, a mean of 2.3% of CD4
+
 and CD8
+
 respectively in Tg-SOD 
and ntg thymus were BrdU
+
 (Table II) and a mean of 0.5% in LN (not shown). After 48 hours, 
the percentage of BrdU
+ 
cells increased in both Tg-SOD and ntg thymus to reach 11.4% ±1.8 
in Tg-SOD versus 9.7% ±4.6 in ntg mice for CD4
+
 SP and 8.3% ±1.2 in Tg-SOD versus 9.4% 
±3.4 in ntg mice for CD8
+
 SP. In LN, the percentage reached 4.3% in Tg-SOD versus 2.4% in 
ntg mice for CD4
+
 SP and 2.5% in Tg-SOD versus 1.8% in ntg mice (not shown). This 
analysis showed that whereas the percentage of BrdU
+
 cells remained similar in Tg-SOD mice 
and ntg control thymus or lymph nodes, the total numbers of BrdU
+
 cells were greater in Tg-
SOD mice, including CD4
+
 and CD8
+
 SP in both organs. 
We further investigated functions of peripheral T cells by measuring their capacity of 
cytokine productions after anti-CD3 antibody stimulation. After 4 hours of culture, cells were 
stained for CD8
FITC
 and CD4
cy
, fixed and stained intracellular for IL-2, IFN-γ, IL-10 and 
TNF-α using PE-labeled mAbs. The percentages of Il-2 producing cells were lower in Tg-
SOD, 36% ±10 for CD4 cells and 18% ±2 for CD8 cells, as compared to ntg mice, 51% ±2 
for CD4 cells and 36% ±10 for CD8 cells (Table III). In addition, the MFIs of IL-2
 
labeling 
were also lower in Tg-SOD mice with 42 ±5 and 37 ±6 for respectively CD4 and CD8 cells as 
compared to 59 ±13 and 50 ±15 respectively in ntg controls. For IFN-γ, the proportion of 
producing CD8 cells is lower in Tg-SOD, 22% ±2, than in ntg mice, 30% ±2. Staining for IL-
10 or for TNF-α did not show any significant difference between the two mice. These data 
showed that peripheral T cells from Tg-SOD mice have the same capacity of activation than 
control mice and responded by a duly cytokine production, although IL-2 and IFN-γ 
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productions appeared to be statistically decreased, suggesting a reduction in Th1 type of 
response.  
 
DISCUSSION 
 Previous studies report that transgenic mice over expressing Cu/Zn superoxyde dismutase 
exhibit various immune abnormalities [22]. Homozygous mice from the same transgenic line 
used in the present study have been shown by electron microscopy to exhibit a premature 
thymic involution [20, 21].This thymus premature involution is a characteristic for DS 
patients [3, 37] and may be related to SOD1 gene dosage since SOD1 is mostly expressed in 
the human thymic medulla [38]. The involution of the thymus is recognized as the most 
prominent features of age-related immune senescence [13, 39, 40]. Thymic involution is 
associated with a gradual decline in the size of the thymus. It has been proposed that thymic 
involution is due to alterations of the intrathymic T-cell development [41]. We studied by 
multiparameter flow analysis the T-cell differentiation of Tg-SOD mice versus ntg control 
littermates in order to evaluate if premature involution reflects a dysfunction of early stages of 
thymus development. Indeed, we showed that Tg-SOD thymus exhibits a transient atrophy, 
with an early thymic development (Tab. 1). The colonization of the thymus was shown to 
happen earlier than in control, following a more rapid decrease from day 140. This 
observation could explain the earlier thymic architecture disorganization observed in these 
Tg-SOD mice [21]. Moreover, Tg-SOD mice exhibit productions of both CD4
+ 
and CD8
+
 SP 
lymphocytes which appear earlier (Fig 1A.) and which are greater along the development 
until day 100 (Fig 1 B and C) as compared to ntg controls. Several lines of evidence support 
the fact that differentiation of thymocytes is accelerated in Tg-SOD mice. First, as shown by 
the profile of TCRβ expression (Fig 2 A.), mature SP expressing high level of TCR were 
detected for both CD4
+ 
and CD8
+
 cells in Tg-SOD mice as early as day 3 which is in 
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accordance with the observation in DS thymus [21]. Second, using CD69 marker as an 
indicator of positive selection, we showed an earlier activation of both SP in Tg mice (Fig 
2B.) and greater numbers of CD69
+
 cells in DP and both SP lymphocytes until day 100 (Fig 
2C.). Third, it is worth to note that both CD4
+
 and CD8
+
 SP T lymphocytes follow the same 
kinetic of production (Fig 1B and C) supporting the idea that the acceleration of 
differentiation affects similarly both pathways. The BrdU labeling of SP T lymphocytes was 
similar in Tg-SOD and ntg control mice (Table II), showing that the greater production of SP 
in thymus of Tg-SOD mice was not due to an extensive proliferation of these cells in Tg-SOD 
mice. The early maturation of both SP lymphocytes in Tg-SOD mice drives of an early 
emigration of mature T cells to the periphery which can be detected in spleen as early as day 3 
(Fig 3.).The cellularity in lymph nodes showed that the pool of emigrant T cells was greater in 
Tg-SOD mice (Table I) and followed the profile of T cell production in thymus. The 
proliferations of T cells in lymph nodes expressing CD4
+
 or CD8
+
 markers, scored by BrdU 
labeling, were similar in both Tg-SOD and ntg control mice (data not shown) confirming that 
the greater number of peripheral T cells in Tg-SOD mice was due to a larger pool of the 
emigrant T cells in transgenic mice [42-44].  Interestingly, the activity of Cu/Zn SOD 
decreased after day 21 and was reduced by factor two in 3 month old Tg-SOD mice. It is 
noteworthy, that cytokine production assays of peripheral T cells reveal few differences 
between Tg-SOD mice and ntg controls mice, essentially a slight reduction of IL-2 and IFN- 
type Th2 cytokine productions. These data are consistent with previous observation showing 
that over expression of SOD1 does not modify the T cell activation [45]. 
The early thymic development in Tg-SOD mice and the identical proliferation of SP T 
lymphocytes in both mice seems to result from alteration in the DP to SP transition. TCR 
signaling plays a crucial role in regulating thymocyte selection at the DP stage. Thus, the 
affinity/avidity of TCR-MHC interactions leads to negative selection via induction of 
Early thymic development in SOD1 transgenic mice. 
 
 15 
apoptosis. The role of the NF-KB/IkB transcriptional regulatory pathway via TCR signaling 
in positive or negative selection was demonstrated [46, 47]. Although, NF-kB mediates a 
survival signal in mature T cells, decreased activity of the NF-kB/Rel pathway results to 
inhibition of thymic negative selection [48]. Tg mice over-expressing SOD1 down-regulate 
the NF-kB expression after transient focal cerebral ischemia [49]. It was also reported that 
mutant SOD1 altered the phosphorylation of Ikb, the inhibitor of NF-kB translocation into the 
nucleus [50]. These data suggested a direct effect of SOD1 activity or expression on 
modulation of the expression of NF-kB or in the control of NF-kb/Rel pathway. Other data 
support relationship between reactive oxygen species (ROS) and T cell apoptosis [51]. 
Indeed, Hidelman and co-workers have shown that ROS can regulate activated T cell 
apoptosis and T cell responses [52] and that the use of a superoxide dismutase mimetic 
protects T cell from superoxide generation  and cell death [53] therefore suggesting roles for 
bcl2 and Fas-ligand (FasL). Taking into account all these results, we propose that modulation 
of Cu/Zn SOD activity affects the negative selection of T cells in Tg mice and subsequently 
the DP to SP transition. The protective [54-56] or destructive [22, 23, 57, 58] effects of SOD1 
overexpression, which remain controversial [59] in the literature might  be the result of the 
apparent antagonist actions of redox balance on  separate pathways involved in T cell 
proliferation, differentiation and apoptosis. 
 
CONCLUSIONS  
Our detailed analysis of thymus differentiation reveals alteration of early stages of thymus 
development in young hSOD1 transgenic mice. As some thymic and more generally immune 
defects have been also observed in trisomic 16 mice and partial trisomy 16 mice, models of 
trisomy 21 [23, 60], which contain the SOD1 gene; our results can give some explanations 
regarding the immunological status of trisomy 21 persons suffering from high rate of 
Early thymic development in SOD1 transgenic mice. 
 
 16 
infections, malignancies and some autoimmune disorders which can be explain by immune 
defects and particularly imbalance of CD4
+
 subpopulations. These results are in agreement 
with the importance of a better understanding of the role of SOD1 overexpression in the 
immunological status of Down syndrome peripheral lymphocytes as recently shown in a 
preliminary gene expression profile analysis [61]. A better understanding of the role in the 
immune system of SOD1 overexpression will be useful for managing the use of 
pharmacological and/or nutritional anti-oxidant compounds in various pathological 
conditions. 
 
List of Abbreviations: 
BrdU, 5-bromo-2’-deoxyuridine; DN, double negative (CD4-/CD8-) DP, double positive 
(CD4
+
/CD8
+
); mean fluorescence intensity, MFI; Monoclonal antibody (mAb). Non 
transgenic control, ntg; SP, simple positive (CD4
+
 or CD8
+
); SOD1, copper /zinc superoxide 
dismutase; Tg-SOD, transgenic mice overexpressing human SOD1. 
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Table I. Cellularity in thymus, spleen and lymph nodes 
 
Mouse Age 
---------------------------------------------------------------------------------------------------------- 
Thymus* 3 days 6 days 14 days 21 days 84 days 
Tg-SOD 35.6 11.6 268.5 28.1 474.3 19.5 547.6 66.5     154.9 8.6      
ntg controls 7.2 1.2 52.2 5.2 113 5.7 227 45.7       58.3 21.9     
---------------------------------------------------------------------------------------------------------- 
Spleen** 3 days 6 days 14 days 21 days 84 days 
Tg-SOD 44.9 1.7 58.9 2.9 192.5 11.8 296.7 45.6 144.3 14.2  
ntg controls 15.7 1.6 48.7 2.7 175.5 22.5 291.7 33.6 138.2 22.5 
---------------------------------------------------------------------------------------------------------- 
Lymph nodes*** 3 days 6 days 14 days 21 days 84 days  
Tg-SOD nd**** 11.2 1.8 37.5 2 86.7 2.1 34.4 2.1 
ntg controls nd nd  12.3 0.6 40.7 1.5 15.7 2.5 
---------------------------------------------------------------------------------------------------------- 
* Number x10
6
 cells  S.D, a minimum of 6 independent animals for each value. 
** number x10
6
 cells  S.D, 5 to 6 independent animals for each value. 
*** number x10
6
 cells S.D for 10 pooled lymph nodes, 5 to 6 independent animals for each 
value. 
**** nd stands for not done
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Table II. BrdU labeling kinetics of thymocytes 
 
Mouse BrdU labeling 
---------------------------------------------------------------------------------------- 
Thymus 4 hours 48 hours 
 SP CD4
+
 SP CD8
+
 SP CD4
+
 SP CD8
+
 
Tg-SOD  % 2.3 0.3 3.3 0.2 11.4 1.8 8.3 1.2 
ntg controls  % 2 0.3 2 +0.6 9.7 4.6 9.4 3.4 
---------------------------------------------------------------------------------------- 
  
* Numbers represent the mean  S.D of percentages of labeled cells from six experiments 
using three individual mice.  
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Table III. T cells cytokine production test 
 
Cytokines                 Mouse 
------------------------------------------------------------------------------------- 
 Tg-SOD ntg controls 
 CD4
+
 CD8
+
 CD4
+
 CD8
+
 
IL-2 % 36 10*** 18 2*** 51 2 36 10 
  MFI 42 5** 37  6* 59 13 50 15 
IFN-γ  % 3.7 0.2 22 2*** 5 2 30 2 
  MFI 81 21 159 31 70 13 128 54 
IL-10  % 2.3 0.6 2 1 3 2 2 0.8 
  MFI 42 7 49 5 42 10 51 4 
TNF-α  % 88 4 84 4* 85 6 73 11 
  MFI 213 34** 98 8*** 173 36 77 13 
-------------------------------------------------------------------------------------- 
 
Numbers represent average percentages of labeled cells and Mean of Fluorescence Intensity 
(MFI) ±SD for the corresponding cytokines in three independent experiments using three 
individual mice.  
*** P≤ 0.0001; ** P≤ 0.001; * P≤ 0.01  
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Figure 1. Phenotype and number of cells in thymus. A. Phenotype of thymocytes in 
homozygous Tg-SOD mice (hSOD1/hSOD1) and ntg controls mice were analyzed by two 
color flow cytometry for expression of CD8 (x axis) and of CD4 (y axis), at day 3 (left panels) 
and day 21 (right panels). 50,000 events were represented on each dot plot. Percentages of 
DP, CD4
+
 SP and CD8
+ 
SP are indicated along each relevant area of the plot. B and C. 
Numbers of CD4
+
 SP and CD8
+
 SP thymocytes respectively are expressed in millions of 
thymocytes (x10
6
) for homozygous Tg-SOD mice (open circle) and in ntg control mice (black 
circle). A minimum of six animals were tested for each point. 
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Figure 1 
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Figure 2. Expression of TCR and CD69 marker. Expressions of TCRβ chain (A) or CD69 
marker (B) in thymocytes from homozygous Tg-SOD mice (hSOD1/hSOD1) (grey area) and 
ntg controls mice (black area) were analyzed by flow cytometry at day 3 (left panels) and day 
21 (right panels). Dotted line represents the APC-conjugated streptavidin alone as background 
fluorescence. Horizontal bar indicates areas considered as high expression of markers. C. 
Numbers of CD69
+
 cells in DP, CD4
+
 SP and CD8
+
 SP thymocytes from homozygous Tg-
SOD mice (open circle) and in ntg control mice (black circle) are expressed in millions of 
thymocytes (x10
6
). A minimum of six animals were tested for each point. 
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Figure 2 
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Figure 3. Phenotype of T lymphocytes in spleen at day 3 and day 21.  
Phenotype of T lymphocytes from spleen of homozygous Tg-SOD mice (hSOD1/hSOD1) 
(top panels) and ntg control mice(bottom panels) were analyzed by two color flow cytometry 
for expression of CD8 (x axis) and of CD4 (y axis), at day 3 (left panels) and day 21 (right 
panels). 50,000 events were represented on each dot plot. Percentages of cells expressing 
either CD4 or CD8 and of unstained cells are indicated in relevant area of the plot. A 
minimum of six animals were tested for each point. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
